Core Viewpoint - Coherus BioSciences, Inc. has entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of its Udenyca franchise for up to $558.4 million, which includes an upfront payment of $483.4 million and potential milestone payments of $75 million [1][2]. Group 1: Financial Implications - The transaction proceeds will be used to fully repay $230 million in existing convertible notes due April 2026 and $49.1 million to buy out certain royalty obligations related to Udenyca [2]. - The deal is expected to close by the end of Q1 2025 [3]. Group 2: Strategic Focus - The divestiture aligns with the company's strategy to concentrate R&D and commercial resources on its innovative immuno-oncology portfolio [2]. - Coherus plans to advance its immuno-oncology portfolio in combination with Loqtorzi, a next-generation PD-1, which is marketed in the U.S. for two indications [3]. Group 3: Future Development Plans - Additional partnerships evaluating Loqtorzi with other cancer agents are planned for 2025 [4]. - Coherus intends to initiate a Phase 2 trial of casdozokitug/toripalimab/bevacizumab in first-line hepatocellular carcinoma in Q4 2024, with final data from a Phase 2 trial in Q1 2025 [4]. - The company plans to report Phase 1 monotherapy biopsy data and combination safety data in head and neck squamous cell carcinoma in 1H 2025 [4]. Group 4: Recent Performance - Following the announcement, CHRS stock increased by 41.6%, reaching $1.94 [6].

Financial Data and Key Metrics Changes - Coherus BioSciences reported total net product revenue of $70.6 million for Q3 2024, a 21% increase compared to Q2 2024 [22] - UDENYCA revenue reached $66 million in Q3 2024, reflecting a 30% increase from Q2 2024 and a 100% increase from Q3 2023 [10][22] - LOQTORZI net revenue was $5.8 million in Q3 2024, a 54% increase quarter-over-quarter [22] - The net loss for Q3 2024 was $10.8 million, or $0.09 per diluted share, compared to a net loss of $39.6 million, or $0.41 per diluted share for the same period in 2023 [54] Business Line Data and Key Metrics Changes - UDENYCA maintained its number 2 position in the market with nearly 30% market share, despite a temporary supply interruption [10][29] - LOQTORZI sales grew 54% quarter-over-quarter, indicating strong execution against the launch plan [16][22] - The UDENYCA franchise saw a 30% increase in revenue from Q2 to Q3 2024, driven by a 54% increase in demand for the on-body presentation [27] Market Data and Key Metrics Changes - UDENYCA's market share in the pegfilgrastim class is approximately 28% [29] - The estimated market for nasopharyngeal carcinoma (NPC) is valued at $150 million to $200 million, with expectations for LOQTORZI to achieve a dominant market share position [25] Company Strategy and Development Direction - The company is focused on a four-part strategy to deliver long-term shareholder value: driving top-line growth, controlling operating expenses, advancing the pipeline, and improving capital structure [9][20] - Coherus is expanding its supply chain by bringing an additional labeling and packaging CMO online, aiming to double its capacity to over one million UDENYCA units annually [15] - The company is advancing a pipeline of innovative immune-oncology drug candidates, targeting large patient populations and high unmet needs [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of UDENYCA sales post-supply interruption, with expectations for robust replenishment in the supply chain [65] - The management team highlighted the importance of customer relationships and the innovative features of UDENYCA in driving future demand [68] - The company anticipates substantial market share increases for UDENYCA in 2025 and beyond [15] Other Important Information - The company is reducing the high end of its expected range of combined R&D and SG&A expenses for 2024 to $250 million to $260 million [56] - Cash equivalents and investments in marketable securities were $97.7 million as of September 30, 2024, down from $117.7 million at year-end [55] Q&A Session Summary Question: What are the expectations for the casdo and tori trial in second line lung cancer? - Management noted that they are encouraged by previous data sets showing partial responses in PDL1 refractory subjects and are proceeding with a stage design for the ongoing study [60][61] Question: Can you clarify when UDENYCA will be available in the commercial channel again? - Management expects sales to resume in late November to early December, with robust replenishment anticipated [65][66] Question: What is the expected response rate benchmark for docetaxel in the casdozo trial? - The baseline docetaxel overall response rate is around 12%, and the company aims for an increment over that in their ongoing study [73] Question: Will there be any impact on customer purchasing volumes due to the supply disruption? - Management indicated that there have been no indications from customers about purchasing in less volume as they diversify their supply chains [80]

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 90%. A quarter ago, it was expected that this drug developer would post a loss of $0.21 per share when it actually produced a loss of $0.14, delivering a surprise of 33.33%.Over the last four quarters, the company has ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact ...

Exhibit 99.1 Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update – Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarterover-quarter– – UDENYCA labeling and packaging production resuming at third-party contract manufacturing organization – – LOQTORZI® launch progressing to plan, revenues increase 50% quarter-over-quarter – –Innovative immuno-oncology pipeline advancing to proof-of-concept studies in combination with toripali ...

– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging production resuming at third-party contract manufacturing organization – – LOQTORZI® launch progressing to plan, revenues increase 50% quarter-over-quarter – – Innovative immuno-oncology pipeline advancing to proof-of-concept studies in combination with toripalimab – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEW ...

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ("Coherus," NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Jami Taylor - Head of Investor Relations Dennis Lanfear - President and Chief Executive Officer Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Rosh Dias - Chief Medical Officer Bryan McMichael - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. Douglas Tsao - H.C. Wainwright & Co. Billal Jahangiri - Truist Securitie ...

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this drug developer would post a loss of $0.05 per share when it actually produced a loss of $0.32, delivering a surprise of -540%. Over the last four quarters, the company ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact Name ...